Scout | Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3

This opportunity is no longer accepting applications.

grant

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

This grant opportunity aims to support the creation and development of medications to prevent and treat opioid and psychostimulant use disorders, as well as overdoses. It involves two phases through the UG3/UH3 Phase Innovation Awards Cooperative Agreement. The first phase (UG3) lasts for two years, where projects must meet certain milestones to qualify for the second phase (UH3), which provid…

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Drug Abuse

Program: SBIR

Award

Award Ceiling: $3M

Funding Amount: $3M

Dates

Opportunity Released: September 1, 2022

Open for Submission: September 1, 2022

Submission Deadline: September 1, 2025

Application Window Closes: September 1, 2025

Keywords

Opioid use disorders

Psychostimulant use disorders

Medication development

FDA approval

NIDA

Preclinical research

Clinical research

Drug discovery

Overdose prevention

UG3/UH3 Phase.

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers